Note: KRAS has been studied in colorectal cancer impacting on treatment program/no indication if ovarian cancer/Lynch Syndrome patients were included
Conclusions: These findings strongly support the hypothesis that
the KRAS-variant is a genetic marker of an increased risk of
developing ovarian
cancer,
and suggests that the KRAS- variant may be a new biomarker
of risk for HBOC families without other known genetic
abnormalities. In addition, the KRAS-variant predicts for the
most deadly ovarian
cancers,
which are likely the most important to prevent or catch
early.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.